Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi


CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 38, Issue 2

Issues

Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells

Candace Miethe / Megan Zamora / Linda Torres / Kelsie G. Raign / Curissa J. Groll / Ramona S. Price
  • Corresponding author
  • Texas State University, Family and Consumer Sciences, Nutrition, San Marcos, TX, USA
  • Ramona Salcedo Price, 601 University Dr, San Marcos, TX 78666, USA, Phone: +512-245-6202
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-03-27 | DOI: https://doi.org/10.1515/hmbci-2018-0068

Abstract

Background

Obesity, a major public health concern, increases the risk of developing liver cancer which is the leading cause of cancer-related deaths worldwide. Obesity is associated with increased adiposity and macrophage infiltration both of which promote secretion of adipokines and cytokines in the tumor microenvironment. Specifically, visfatin and resistin have been detected at higher levels in the serum of obese individuals and liver tumors. However, the contribution of these adipocytokines in the progression of liver cancer remains unclear.

Materials and methods

The objective of this study was to characterize the effects of visfatin and resistin on HepG2, SNU-449 and HuH7 liver cancer cells. Cells exposed to visfatin and resistin were analyzed for fatty acid synthase protein, and phosphorylation of Akt and ERK tumorigenic signaling pathways, cell viability, lipogenesis, reactive oxygen species (ROS), matrix metallopeptidase 9 (MMP-9) enzyme activity and invasion.

Results

HepG2, SNU-449, and HuH7 liver cancer cells treated with visfatin and resistin increased cell viability, invasion, FASN protein, and Akt and ERK phosphorylation. Visfatin and resistin selectively increased ROS production in HepG2 and SNU-449 cells while there was no statistical difference in HuH7 cells. Visfatin and resistin stimulated lipogenesis in HepG2 cells while visfatin increased lipogenesis in SNU-449 cells, and visfatin nor resistin had an effect on lipogenesis in HuH7 cells. Lastly, visfatin and resistin increased MMP-9 enzyme activity in HepG2 and HuH-7 cells but only visfatin increased MMP-9 activity in SNU-449 cells.

Conclusions

Future studies are needed to determine if inhibition of ERK and Akt suppresses the visfatin and resistin-induced invasive liver cancer phenotype.

Keywords: adipocytokines; cytokines; liver cancer; obesity; resistin; visfatin

References

  • [1]

    The American Cancer Society. About Liver Cancer. https://www.cancer.org/cancer/liver-cancer/about.html. Accessed: October 21, 2017.

  • [2]

    CDC. Adult Obesity Facts. http://www.cdc.gov/obesity/data/adult.html. Accessed: October 21, 2017.

  • [3]

    Sun B, Karin M. Obesity, inflammation and liver cancer. J Hepatol. 2012;56:704–13.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [4]

    Miethe C, Nix H, Martin R, Hernandez AR, Price RS. Silibinin reduces the impact of obesity on invasive liver cancer. Nutr Cancer. 2017;69:1272–80.Web of SciencePubMedCrossrefGoogle Scholar

  • [5]

    Ninomiya S, Shimizu M, Imai K, Imai K, Takai K, Shiraki M, et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev Res (Phila). 2011;4:2092–100.CrossrefPubMedGoogle Scholar

  • [6]

    Zhang Z, Shannon J, Zhang H. Resistin, obesity, and cancer. In: Reizes O, Berger N, editors. Adipocytokines, energy balance, and cancer, Vol. 12. Cham, Switzerland: Springer; 2017.Google Scholar

  • [7]

    Dalamaga M, Christodoulatos GS. Visfatin, obesity, and cancer. In: Reizes O, Berger N, editors. Adipocytokines, energy balance, and cancer, Vol. 12. Cham, Switzerland: Springer; 2017.Google Scholar

  • [8]

    El-Shafey EM, El-Naggar GF, Al-Bedewy MM, El-Sorogy H. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients? J Diabetes Metab. 2012;S11:001. DOI: .CrossrefGoogle Scholar

  • [9]

    Filippatosm TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B colony-enhancing factor in obese and overweight patient with metabolic syndrome. J Endocrinol Invest. 2007;30:323–6.PubMedCrossrefGoogle Scholar

  • [10]

    Chen M-P, Chung F-M, Chang D-M, Tsai JC, Huang H-F, Shin S-J, et al. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:295–9.CrossrefPubMedGoogle Scholar

  • [11]

    Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:997–1001.PubMedCrossrefGoogle Scholar

  • [12]

    Nieva-Vazquez A, Pérez-Fuentes R, Torres-Rasgado E, López-López JG, Romero JR. Serum resistin levels are associated with adiposity and insulin sensitivity in obese Hispanic subjects. Metab Syndr Relat Disord. 2014;12:143–8.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [13]

    Akhtar A, Saeed M, Shakoor Q. Relationship of serum resistin and lipid profile in type 2 diabetics. Pak J Physiol. 2017;13:3–5.Google Scholar

  • [14]

    Mounier C, Bouraoui L, Rassart E. Lipogenesis in cancer progression. Int J Oncol. 2014;45:485–92.CrossrefPubMedGoogle Scholar

  • [15]

    Hikita H, Kodama T, Tanak S, Saito Y, Nozaki Y, Nakabor T, et al. Activation of the mitochondrial apoptotic pathway produces reactive oxygen species and oxidative damage in hepatocytes that contribute to liver tumorigenesis. Cancer Prev Res (Phila). 2015;8:693–701.PubMedCrossrefGoogle Scholar

  • [16]

    Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [17]

    He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010:17;286–97.Web of SciencePubMedCrossrefGoogle Scholar

  • [18]

    Chen JS, Huang XH, Wang Q, Huang JQ, Zhang LJ, Chen XL, et al. Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. 2012;34:10–9.Web of SciencePubMedGoogle Scholar

  • [19]

    Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, et al. Differential requirements for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016;63:1900–13.CrossrefGoogle Scholar

  • [20]

    Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta. 2011;1807:664–78.Web of ScienceCrossrefGoogle Scholar

  • [21]

    Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–89.CrossrefWeb of ScienceGoogle Scholar

  • [22]

    AL-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [23]

    Redondo M, Rodriguez L, Haymond M, Hampe CS, Smith EO, Balasubramanyam A, et al. Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2014;15:543–9.CrossrefWeb of SciencePubMedGoogle Scholar

  • [24]

    Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O, et al. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep. 2014;31:573–80.Web of ScienceCrossrefPubMedGoogle Scholar

  • [25]

    Fan Y, Meng S, Wang Y, Cao J, Wang C. Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway. Int J Mol Med. 2011;27:607–15.Web of SciencePubMedGoogle Scholar

  • [26]

    Luo Z, Zhang Y, Li F, He J, Ding H, Yah L, et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine. 2009;36:60–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [27]

    Nieva-Vazquez A, Pérez-Fuentes R, Torres-Rasgado E, López-López JG, Romero JR. Serum resistin levels are associated with adiposity and insulin sensitivity in obese Hispanic subjects. Metab Syndr Relat Disord. 2014;12:143–8.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [28]

    Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042–53.PubMedCrossrefGoogle Scholar

  • [29]

    Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab. 2007;92:270–6.Web of SciencePubMedCrossrefGoogle Scholar

  • [30]

    Ding Q, Chai H, Mahmood N, Tsao J, Mochly-Rosen D, Zhou W. Matrix metalloproteinases modulated by pkcε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg. 2011;53:1044–51.CrossrefPubMedGoogle Scholar

  • [31]

    Lee JO, Kim N, Lee HJ, Lee YW, Kim SJ, Park SH, et al. Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep. 2016;6:18923.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [32]

    Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:997–1001.PubMedCrossrefGoogle Scholar

  • [33]

    Akhtar A, Saeed M, Shakoor Q. Relationship of serum resistin and lipid profile in type 2 diabetics. Pak J Physiol. 2017;13:3–5.Google Scholar

About the article

Received: 2018-09-24

Accepted: 2019-02-14

Published Online: 2019-03-27


Author Statement

Research funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest: None declared.

Informed consent: Not applicable.

Ethical approval: Not applicable.


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 38, Issue 2, 20180068, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2018-0068.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in